Last reviewed · How we verify

Ayvakit — Competitive Intelligence Brief

Ayvakit (AVAPRITINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Platelet-derived growth factor receptor alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ayvakit (AVAPRITINIB) — Blueprint Medicines. Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ayvakit TARGET AVAPRITINIB Blueprint Medicines marketed Kinase Inhibitor [EPC] Platelet-derived growth factor receptor alpha 2020-01-01
Lartruvo OLARATUMAB Eli Lilly marketed Platelet-derived Growth Factor Receptor alpha Antagonist Platelet-derived growth factor receptor alpha 2016-01-01
Hernexeos ZONGERTINIB Boehringer Ingelheim marketed Kinase Inhibitor [EPC] 2025-01-01
Wayrilz RILZABRUTINIB Genzyme Corp marketed Kinase Inhibitor [EPC] 2025-01-01
Romvimza VIMSELTINIB Deciphera Pharms marketed Kinase Inhibitor [EPC] 2025-01-01
Itovebi INAVOLISIB Genentech Inc marketed Kinase Inhibitor [EPC] 2025-01-01
Ojemda TOVORAFENIB Day One Biopharms marketed Kinase Inhibitor [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ayvakit — Competitive Intelligence Brief. https://druglandscape.com/ci/avapritinib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: